TW202144381A - 用於炎症之化合物 - Google Patents

用於炎症之化合物 Download PDF

Info

Publication number
TW202144381A
TW202144381A TW110107292A TW110107292A TW202144381A TW 202144381 A TW202144381 A TW 202144381A TW 110107292 A TW110107292 A TW 110107292A TW 110107292 A TW110107292 A TW 110107292A TW 202144381 A TW202144381 A TW 202144381A
Authority
TW
Taiwan
Prior art keywords
substituted
unsubstituted
compound
day
virus
Prior art date
Application number
TW110107292A
Other languages
English (en)
Chinese (zh)
Inventor
蘇薩 何塞 瑪麗亞 費爾南德斯
馬里昂 佩巴羅 阿維萊斯
岡薩雷斯 亞歷杭德羅 落撒達
Original Assignee
西班牙商瑪製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 西班牙商瑪製藥股份有限公司 filed Critical 西班牙商瑪製藥股份有限公司
Publication of TW202144381A publication Critical patent/TW202144381A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110107292A 2020-03-02 2021-03-02 用於炎症之化合物 TW202144381A (zh)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382152.5 2020-03-02
EP20382192 2020-03-13
EP20382192.1 2020-03-13
EP20382266.3 2020-04-02
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382339.8 2020-04-27
EP20382815.7 2020-09-16
EP20382816 2020-09-16
EP20382816.5 2020-09-16
EP20382815 2020-09-16
EP21382059 2021-01-25
EP21382059.0 2021-01-25

Publications (1)

Publication Number Publication Date
TW202144381A true TW202144381A (zh) 2021-12-01

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110107292A TW202144381A (zh) 2020-03-02 2021-03-02 用於炎症之化合物
TW110107293A TWI908772B (zh) 2020-03-02 2021-03-02 用於病毒感染之化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110107293A TWI908772B (zh) 2020-03-02 2021-03-02 用於病毒感染之化合物

Country Status (17)

Country Link
US (2) US12630589B2 (cg-RX-API-DMAC7.html)
EP (2) EP4114433A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023517536A (cg-RX-API-DMAC7.html)
KR (2) KR20220151643A (cg-RX-API-DMAC7.html)
CN (2) CN115666616A (cg-RX-API-DMAC7.html)
AU (2) AU2021232535A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022016604A2 (cg-RX-API-DMAC7.html)
CA (2) CA3169540A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002396A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022014031A2 (cg-RX-API-DMAC7.html)
IL (2) IL296069A (cg-RX-API-DMAC7.html)
MX (2) MX2022010921A (cg-RX-API-DMAC7.html)
PE (2) PE20230412A1 (cg-RX-API-DMAC7.html)
PY (2) PY2117301A (cg-RX-API-DMAC7.html)
TW (2) TW202144381A (cg-RX-API-DMAC7.html)
UY (2) UY39110A (cg-RX-API-DMAC7.html)
WO (2) WO2021175831A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114436A1 (en) * 2020-03-02 2023-01-11 Pharma Mar S.A. Compounds for use in the treatment of coronavirus infection
CN115666616A (zh) 2020-03-02 2023-01-31 法马马有限公司 用于病毒感染的化合物
IL296067A (en) * 2020-03-02 2022-11-01 Pharma Mar Sa Pld for use in combination in the treatment of coronavirus
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
BR9909668A (pt) * 1998-04-14 2000-12-19 Jomaa Hassan Uso de compostos de organofósforo para o tratamento terapêutico e profilático de infecções
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP4623931B2 (ja) * 2000-12-07 2011-02-02 エンセラデュス、ファーマシューティカルズ、ベスローテン、フェンノートシャップ 炎症性疾患の治療用組成物
US20070148192A1 (en) * 2003-02-21 2007-06-28 Laddha Ritu N Stable ophthalmic composition
AU2004224418A1 (en) 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
JP5814933B2 (ja) * 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
US20120040033A1 (en) * 2010-08-10 2012-02-16 Ernest Timothy Armstrong Anti-infective mangrove extract against viruses, bacteria and fungi
GB201316524D0 (en) * 2013-09-17 2013-10-30 Medical Res Council Biomarkers
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
US11771739B2 (en) * 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
CN115666616A (zh) * 2020-03-02 2023-01-31 法马马有限公司 用于病毒感染的化合物

Also Published As

Publication number Publication date
CO2022014093A2 (es) 2022-11-18
KR20220151643A (ko) 2022-11-15
PE20230606A1 (es) 2023-04-10
BR112022016675A2 (pt) 2022-10-11
JP2023517535A (ja) 2023-04-26
CN115461067A (zh) 2022-12-09
PY2117301A (es) 2022-08-09
PE20230412A1 (es) 2023-03-07
UY39110A (es) 2021-09-30
US20230295236A1 (en) 2023-09-21
WO2021175831A2 (en) 2021-09-10
US20230159594A1 (en) 2023-05-25
CO2022014031A2 (es) 2022-10-21
EP4114433A2 (en) 2023-01-11
CN115666616A (zh) 2023-01-31
AU2021232535A1 (en) 2022-10-06
WO2021175831A3 (en) 2021-10-14
UY39109A (es) 2021-09-30
BR112022016604A2 (pt) 2022-10-11
IL296069A (en) 2022-11-01
MX2022010921A (es) 2022-09-29
CA3169544A1 (en) 2021-09-10
US12630589B2 (en) 2026-05-19
EP4114435A1 (en) 2023-01-11
TWI908772B (zh) 2025-12-21
WO2021175857A1 (en) 2021-09-10
KR20220150350A (ko) 2022-11-10
IL296068A (en) 2022-11-01
TW202146038A (zh) 2021-12-16
CL2022002396A1 (es) 2023-06-30
JP2023517536A (ja) 2023-04-26
CL2022002395A1 (es) 2023-06-30
AU2021231197A1 (en) 2022-10-06
MX2022010926A (es) 2022-09-29
PY2117308A (es) 2022-08-09
CA3169540A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
Kaddoura et al. COVID-19 therapeutic options under investigation
US20230295236A1 (en) Compounds for use in inflammatory conditions
Ahidjo et al. Current perspective of antiviral strategies against COVID-19
KR20200131784A (ko) 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
Duan et al. Current and future therapeutical approaches for COVID-19
Kalam et al. Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies
US20230158103A1 (en) Pld for use in combination in the treatment of coronavirus
WO2019141263A1 (zh) 一种广谱抗肠道病毒的多肽及其应用
Kaur et al. A comprehensive review on epidemiology, aetiopathogenesis, diagnosis and treatment of the novel coronavirus syndrome–COVID-19
CN109414508A (zh) 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
EA050436B1 (ru) Соединения для применения при воспалительных состояниях
TW202144380A (zh) 用於治療冠狀病毒感染之化合物
Gazina et al. Viral targets of acylguanidines
JP2007015926A (ja) C型肝炎治療剤
Frediansyah et al. Clinical Epidemiology and Global Health
Singh et al. Potential antiviral therapies for coronavirus disease 2019 (COVID-19)
Fan et al. Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities
Jose et al. Analyzing the Impermeable Structure and Myriad of Antiviral Therapies for SARS-CoV-2
Solomon Investigating the role of cellular metabolism in human coronavirus replication
EA050340B1 (ru) Соединения для применения в лечении коронавирусной инфекции
Ortiz et al. New Drugs in Synthesis Research for Viral Diseases
Modak A review on the pathophysiology and potential drugs for Covid-19
CN118320091A (zh) 胱天蛋白酶抑制剂的组合物及其使用方法